Skip to main content
FDA approves Adcetris for classical Hodgkin lymphoma

Adcetris, or brentuximab vedotin, received FDA approval for use with chemotherapy in treatment-naive patients with stage III or IV classical Hodgkin lymphoma. The therapy combines an anti-C30 antibody with monomethyl auristatin E to target lymphoma cells.

Full Story: